BioCardia, Inc. · NASDAQ:BCDA

BioCardia — ARM Partnering Presentation (October 2015)

17 slides from BioCardia's conference presentation, Oct 7, 2015

  1. Slide 1: ARM Partnering Presentation

    Filed Pursuant to Rule 433 under the Securities Act of 1933 Issuer Free Writing Prospectus dated October 6, 2015 Relating to Preliminary Prospectus dated July 13, 2015 Registration No. 333-205003 ARM Partnering Presentation October 7, 2015 1 Confidential – Do Not Distribute 04423-A (MKT)

  2. Slide 2: Disclaimer Regarding Forward-Looking Statements

    Disclaimer Regarding Forward-Looking Statements Any statements made about the company’s anticipated financial results are forward-looking statements subject to risks and uncertainties such as the results from ongoing clinical trials, the regulatory approval of the company’s products, the ability of

  3. Slide 3: Free Writing Prospectus Legend

    Free Writing Prospectus Legend BioCardia, Inc. (the “Company”) has filed a registration statement (including a preliminary prospectus) with the Securities and Exchange Commission (the “SEC”) for the offering to which this communication relates. Before you invest, you should read the prospectus in th

  4. Slide 4: BioCardia Strengths

    BioCardia Strengths  From concept to pivotal heart failure trial on less than $40M  Only Phase III heart failure cell therapy program we are aware of with:  Blinded randomized placebo controlled Phase II  Companion diagnostic  PMA CBER regulatory pathway  Only company we are aware of that has

  5. Slide 5: BioCardia's cell therapy programs and enabling device platforms

    BioCardia’s cell therapy programs and enabling device platforms 5 04423-A (MKT)

  6. Slide 6: CardiAMP cell therapy in heart failure, a novel and rapid treatment

    CardiAMP cell therapy in heart failure, a novel and rapid treatment Initiating FDA accepted Phase III pivotal trial, anticipate topline data 2018 6 04423-A (MKT)

  7. Slide 7: Pre-procedure Marrow Potency Assay

    CardiAMP: Pre-procedure Marrow Potency Assay  Proprietary biomarker panel analysis at core lab qualifies patients most responsive to therapy and significantly reduce the cost of autologous cell therapy  Biomarkers from BioCardia trials and scientific literature are shown to correlate independently

  8. Slide 8: CardiAMP Procedure Step 1: Cell Collection

    CardiAMP Procedure Step 1: Cell Collection  The clinician draws ~60cc of bone marrow from the iliac crest (hip bone)  The procedure is performed under local anesthesia and conscious sedation and takes approximately 15 minutes 1 Loffredo FS et al Stem Cell. 2011;8:389-98. 8 04423-A (MKT)

  9. Slide 9: CardiAMP Procedure Step 2: Cell Processing

    CardiAMP Procedure Step 2: Cell Processing  The CardiAMP cell processing platform prepares the proprietary dosage form at point of care by concentrating the nucleated cells in the bone marrow sample uses approved technology exclusively licensed from Biomet Biologics.  The system includes a single-

  10. Slide 10: CardiAMP Procedure Step 3: Delivery

    CardiAMP Procedure Step 3: Delivery Cells infused using Helix™ system to patients heart  CardiAMP cells are injected into the heart tissue using our proprietary Helix biotherapeutic delivery system by a cardiologist in a procedure taking approximately 15 to 30 minutes. Helix is available for partne

  11. Slide 11: CardiAMP: Phase I Trial Design and Results

    CardiAMP: Phase I Trial Design and Results 20 Ischemic Heart Failure Patients EF<40% NYHA Class I, II, and III 20 patients @ 100M BMC* cells No control arm  Cells were prepared and counted for CD34+ content. Cells delivered at up to 10 peri-infarct sites using the Helix system  Two-dimensional tra

  12. Slide 12: CardiAMP: Phase II Trial Design

    CardiAMP: Phase II Trial Design Patients Randomized into Two Autologous Cell Trials: BMC* and MSC** 68 Ischemic Heart Failure Patients EF<50% NYHA Class I, II, and III --CardiAMP ARM-- 4 Patients dose escalation 4 Patients dose escalation 100M to 200M BMC 100M to 200M MSC 10 Patients 20 Patients 10

  13. Slide 13: CardiAMP: Phase II Results

    CardiAMP: Phase II Results  CardiAMP cells met the primary safety endpoint with no treatment related major adverse cardiac events at 30 days  Cells were associated with statistically and clinically significant improvements in functional capacity as measured by the six minute walk test and improvem

  14. Slide 14: Phase II Trial Results from TAC-HFT - BMC

    CardiAMP: Phase II Trial Results from TAC-HFT - BMC Change in functional capacity as Change in quality of life measured by six minute walk distance as measured by Minnesota living with at 12 months (meters) heart failure questionnaire (points) Better Worse Worse Better Improved functional capacity I

  15. Slide 15: Phase III Trial Design – Replicating Phase II Success

    CardiAMP: Phase III Trial Design – Replicating Phase II Success 250 Ischemic Heart Failure Patients 20% ≤ EF ≤ 40% NYHA Class II and III CardiAMP Potency Assay Score of 3 150 Patients @200M Cells 100 Patients SHAM  Changes from Phase II are NYHA Class I patients are eliminated and potency assay is

  16. Slide 16: Current Phase III Programs in Cell Therapy for Heart Failure

    Current Phase III Programs in Cell Therapy for Heart Failure VALUE PROPOSITIONS BioCardia Teva/ Mesoblast Celyad CARDIAMP REVASCOR C-CURE Cells Patients own cells, harvested, Patients own cells, provided in Someone else’s cells, provided in one cultured, one time therapy in 60 minutes time therapy o

  17. Slide 17: www.BioCardia.com

    www.BioCardia.com Contact: Peter Altman CEO BioCardia, Inc. paltman@biocardia.com 650-226-0120 17 Confidential – Do Not Distribute

BioCardia — ARM Partnering Presentation (October 2015) on 6ix